Guggenheim analyst Debjit Chattopadhyay initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $19 price target The company has advanced three small molecules into clinical development by leveraging its Compass platform, the analyst tells investors in a research note. The firm says Maze is positioned to be the second entrant in APOL1-mediated kidney disease, which it believes could morph into a $10B to $15B total addressable market. The company’s current $200M enterprise value “offers a compelling entry point for investors with a 12-month horizon,” contends Guggenheim.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue